Sandoz is introducing Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz, the first and only interchangeable FDA-approved denosumab biosimilars and are approved to treat all indications of Amgen’s ...
Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC approval based on robust development program confirming that ...
WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves access for patients living with osteoporosis and ...
The Food and Drug Administration announced the approval of 127 innovator and biosimilar drugs in 2024, a notable decrease from the 149 approvals recorded in 2023. Despite the decline in overall ...
Investing.com -- Sandoz Group AG (SIX:SDZ) on Wednesday reported full-year 2025 results that met analyst expectations and issued fiscal 2026 guidance slightly above consensus, signaling confidence in ...
Europe net sales grew by 7%[1]. International declined by 2%[1] and increased by 2% when adjusted for China divestment. Net sales in North America grew by 1%[1] and, adjusted for Cimerli acquisition, ...
The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry. The FDA has approved ...
WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves access for patients living with osteoporosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results